Cynthia Collins

Cynthia Lynne Collins is Executive Chairman & Chief Executive Officer at Nutcracker Therapeutics, Inc. starting in 2025.
Holds director roles at Cavidi AB since 2018, Analytical Life Science & Diagnostics Association, Panavance Therapeutics, Inc., Alanis Therapeutics, Inc., and The Charles Stark Draper Laboratory, Inc. since 2021.
Independent Non-Executive Director at MaxCyte, Inc. since 2024.
Independent Director at DermTech, Inc. since 2018 and Codexis, Inc. starting in 2025.
Formerly Chief Executive Officer at Clarient, Inc. from 2013 to 2015; President, Chief Executive Officer & Director at GenVec, Inc. from 2012 to 2013; President & Chief Executive Officer at Sequoia Pharmaceuticals, Inc. from 2005 to 2007; Chief Executive Officer & GM-Cell Therapy Business at GE Healthcare, Inc. from 2013 to 2016; President & Chief Executive Officer at Editas Medicine, Inc. in 2021; Chief Executive Officer at Human Longevity, Inc. in 2017; Director at DermTech Operations, Inc. from 2018 to 2019; Director at Biocare Medical LLC from 2018 to 2021; Director at Provista Diagnostics, Inc. in 2018; Independent Director at Poseida Therapeutics, Inc. from 2021 to 2025; Director at Triumvira Immunologics, Inc. from 2018 to 2023; Independent Director at Certara, Inc. from 2021 to 2026; Group Vice President-Cellular Analysis Business at Beckman Coulter, Inc. from 2007 to 2011; President-Global Oncology at Baxter Healthcare SA from 1986 to 2003; President at Clinical Micro Sensors, Inc. from 2004 to 2005.
Education includes an MBA from The University of Chicago Booth School of Business and undergraduate studies at the University of Illinois At Urbana–Champaign.